Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death

Jamieson, Amy; Huvila, Jutta; Chiu, Derek S.; Thompson, Emily F.; Scott, Stephanie; Salvador, Shannon; Vicus, Danielle; Helpman, Limor; Gotlieb, Walter H.; Kean, Sarah; Samouëlian, Vanessa; Köbel, Martin; Kinloch, Mary; Parra-Harran, Carlos; Offman, Saul; Grondin, Katherine; Irving, Julie; Lum, Amy; Senz, Janine; Leung, Samuel; McConechy, Melissa K.; Plante, Marie; Kommoss, Stefan; Huntsman, David G.; Talhouk, Aline; Gilks, C. Blake; McAlpine, Jessica N.

doi:10.1016/j.modpat.2022.100085

Cited by 37 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic value of ER expression has been investigated in recent studies within The Cancer Genome Atlas groups, and remains clinically relevant. 30,31,42 The prognostic value of ER expression appears most relevant in the NSMP group. In the adjuvant treatment setting, a first randomized study is planned to investigate efficacy of adjuvant HT in the NSMP group with advanced EC (ClinicalTrials.gov identifier: NCT05255653).…”

Section: Integration Of Molecular Subgroups With Predictive Biomarkersmentioning

confidence: 99%

“…In fact, HT has a good safety profile, whereas chemotherapy is associated with grade 3 treatment-related toxicity in 35% of the patients, compared with only 6.5% with progestin therapy. [29][30][31] On the basis of these facts, we strongly believe that the position of hormonal drugs for preselected groups of patients with EC should be redefined in the context of the molecular classification. To this end, there are a number of considerations and remaining challenges with current data that should be addressed, as discussed in the following part.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification

Pijnenborg,

van Weelden,

Reijnen

et al. 2024

JCO

View full text Add to dashboard Cite

Section: Integration Of Molecular Subgroups With Predictive Biomarkersmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification

Pijnenborg,

van Weelden,

Reijnen

et al. 2024

JCO

View full text Add to dashboard Cite

“…In contrast to POLEmut ECs, research focusing specifically on NSMP ECs has shown that additional clinicopathologic and molecular features are strongly associated with outcomes and may aid in prognostic and predictive substratification of this molecular subtype. 50…”

Section: Nsmp Endometrial Cancermentioning

confidence: 99%

Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice

Jamieson

McAlpine

2023

Journal of the National Comprehensive Cancer Network

Self Cite

View full text Add to dashboard Cite

Molecular classification provides an objective, reproducible framework for categorization of endometrial cancers (ECs), informing prognosis and selection of therapy. Currently, the uptake of molecular classification, integration in to EC management algorithms, and enrollment in molecular subtype-specific clinical trials lags behind what it could be. Access to molecular testing is not uniform, and subsequent management (surgical, adjuvant therapy) is unacceptably variable. We are in the midst of a critical landscape change in this disease site, with increasing emphasis on the integration of molecular features in EC care that can potentially improve standard of care globally. This article summarizes the rationale for molecular classification of ECs, strategies for implementation in low and high resource settings, and actionable opportunities based on this information.

show abstract

“…8,42 Several studies have focused on this NSMP group and showed that based on PTEN/PIK3CA mutation status, histology/grade, chromosome 1q gain/amplification, ER status or chromosomal instability, subgroups with distinct outcomes could be identified. 14,[43][44][45][46][47] Finally, the CN-H/p53abn/TP53abn ECs, associated with the worst outcome among the four molecular subtypes groups, are genetically heterogeneous and several subgroups harboring potentially targetable alterations have been identified across histologic types. 1,19,24,48 An area of active interest is the ERBB2/ HER2-altered subgroup.…”

Section: Therapeutic Implications Of the Ec Molecular Subtypesmentioning

confidence: 99%

Moving into the modern era of molecular classification for endometrial cancer

Dagher,

Liu,

Mueller

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

The molecular subtypes of endometrial carcinoma (EC) were first described by The Cancer Genome Atlas (TCGA) a decade ago. Using surrogate approaches, the molecular classification has been demonstrated to be prognostic across EC patients and to have predictive implications. Starting in 2020, the molecular classification has been incorporated into multiple guidelines as part of the risk assessment and most recently into the International Federation of Gynecology and Obstetrics (FIGO) staging. This review article discusses the implementation of the EC molecular classification into clinical practice, the therapeutic implications, and the molecular and clinical heterogeneity of the EC molecular subtypes.

show abstract

Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death

Cited by 37 publications

References 31 publications

Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification

Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification

Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice

Moving into the modern era of molecular classification for endometrial cancer

Contact Info

Product

Resources

About